Key Drivers
- Liquidity Buffer
- Negative Equity
- Cash Burn
AIAI Summary
NVAX is shifting from a shaky single-product vaccine bet to a platform-and-partnership story, but the stock remains investable only if management can convert Matrix-M collaborations into recurring cash flow fast enough to offset negative operating cash flow and a fragile balance sheet; until then, liquidity buys time, not safety.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Buffer
- •Negative Equity
- •Cash Burn
Novavax has strong liquidity, margins, and deferred revenue support, but negative equity, recurring cash burn, and a sharp drop from 2025 profitability to a loss in the latest quarter make the investment case highly mixed.
Price Behavior
Key Price Behavior Insights:
- •Support Hold
- •Failed Breakout
- •Momentum Fade
Over the last month, NVAX showed a volatile recovery, repeatedly holding around $7.92-$8.04 support but failing to sustain a break above $10.11, leaving $9.50-$9.62 as near-term resistance and momentum fragile.
Sharp surge to $10.11 on 2026-05-08 quickly reversed to $9.06 by 2026-05-15
Sentiment & News
Key News Insights:
- •Earnings beat
- •Partnership growth
- •Trial momentum
Novavax rallied on a Q1 earnings beat, reaffirmed guidance, and expanding Matrix-M partnership momentum, with added support from positive trial data and broader vaccine-sector strength.
The news is constructive for NVAX, reinforcing near-term upside sentiment by improving fundamentals, validating pipeline progress, and supporting momentum in the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings